Satellos Bioscience Inc.
MSLE Nasdaq
SEC CIK 1421642
Follow Satellos Bioscience
Weekly email: filings, results
Net income
−$24.9M
−20.5% vs prior year
EPS, diluted
−$1.70
+21.3% vs prior year
Operating cash flow
−$23.6M
−29.3% vs prior year
Operating income
−$26.5M
−29.7% vs prior year
Source: SEC XBRL filings · latest filing